ライフサイエンスコーパス: sphingosine-1-phosphate

1 of long-chain base phosphates (LCB-Ps, e.g., sphingosine-1-phosphate).

2 of sphingosine and its bioactive metabolite, sphingosine 1-phosphate.

3 f the potent barrier-enhancing phospholipid, sphingosine 1-phosphate.

4 s observed in response to phorbol esters and sphingosine 1-phosphate.

5 ut it was recruited following treatment with sphingosine-1-phosphate.

6 tol 5' phosphatase 1 activity or by blocking sphingosine-1-phosphate.

7 Amiselimod is an oral selective modulator of sphingosine 1-phosphate 1 (S1P1) receptor, which is bein

8 ion of mice and ferrets by administration of sphingosine-1-phosphate 1 receptor (S1P1R) agonists.

9 against neural injury via modulation of the sphingosine-1-phosphate 1 receptor (S1PR1).

10 Earlier we reported that modulation of sphingosine-1-phosphate-1 receptor (S1P1R) signaling pro

11 inducible gene responsible for generation of sphingosine-1-phosphate, a critical lipid signaling mole

12 kinase isoforms (SphK1 and SphK2) to produce sphingosine-1-phosphate, a mediator essential for MC res

13 and is the major cell type supplying plasma sphingosine-1-phosphate, a signaling lipid regulating mu

14 on neutrophils, and that treatment with the sphingosine-1-phosphate agonist FTY720 altered neutrophi

15 On treatment with a sphingosine-1-phosphate agonist, the frequency of these

16 Like VEGF, sphingosine-1-phosphate also seemed to exert its proangi

17 nregulation can occur after stimulation with sphingosine-1-phosphate (an S1PR1 agonist), whereas S1PR

18 Finally, we have shown that sphingosine 1-phosphate, an endogenous microglial signal

19 2(-/-) mice have lower levels of hippocampal sphingosine-1-phosphate, an endogenous HDAC inhibitor, a

20 hereby controlling production of endothelial sphingosine 1-phosphate and autocrine, G protein-coupled

21 ree dimensions in response to stimulation by sphingosine 1-phosphate and growth factors.

22 (SK1) produces the pro-survival sphingolipid sphingosine 1-phosphate and has been implicated in infla

23 Sphingosine 1-phosphate and the sphingosine 1-phosphate

24 vitro chemotaxis to chemoattractants such as sphingosine-1-phosphate and CXCL12.

25 Ca(2+)-mobilizing agents sphingosine-1-phosphate and cyclic adenosine diphosphate

26 ressing podocytes had higher basal levels of sphingosine-1-phosphate and maintained basal ceramide le

27 Thus, sphingosine-1-phosphate and SphK2 play specific roles in

28 similar lipids, such as phosphatidylserine, sphingosine 1-phosphate, and phosphatidic acid, could no

29 ctive sphingolipid metabolite sphingosine to sphingosine-1-phosphate, and suggested a role for sphing

30 ion include thrombin, lysophosphatidic acid, sphingosine-1-phosphate, and thromboxane A2.

31 application of fingolimod, an established SK/sphingosine-1-phosphate antagonist already in clinical u

32 ingosine to produce the key signaling lipid, sphingosine 1-phosphate, are described.

33 lipid metabolites, particularly ceramide and sphingosine-1-phosphate, are signalling molecules that r

34 mmation involves the sphingosine kinase (SK)/sphingosine-1-phosphate axis.

35 immediate relevance for our understanding of sphingosine-1-phosphate biosynthesis, signaling, and deg

36 lysophosphatidic acid, phosphatidic acid, or sphingosine-1-phosphate but surprisingly not for the nat

37 ortance of sphingosine and its conversion to sphingosine-1-phosphate by SphK1 in endocytic membrane t

38 nanoparticles) containing elevated levels of sphingosine-1-phosphate, CCL20 and prostaglandin E2 (PGE

39 We demonstrate the biological effect of sphingosine-1-phosphate contained in IDENs on tumour gro

40 we demonstrate that the main product of SK1, sphingosine-1-phosphate, controls the migration of intra

41 viously shown that sphingolipid signaling by sphingosine 1-phosphate decreases basal P-glycoprotein t

42 s formation of the biologically active lipid sphingosine 1-phosphate, drives a malicious amplificatio

43 se from acidic stores that is independent of sphingosine 1-phosphate, extracellular and ER calcium le

44 Sphingosine fluorescein (SF), sphingosine-1-phosphate fluorescein (S1PF), and a third

45 ter than 50% reduction after incubation with sphingosine 1-phosphate, FTY720, or other sphingosine 1-

46 (SGPL1)-a key enzyme for the creation of the sphingosine-1 phosphate gradient, which is relevant to t

47 pheral lymph nodes of immunized mice lacking sphingosine-1-phosphate had impaired HEV integrity simil

48 Sphingosine 1-phosphate has an important role in kidney

49 Because both FTY720 and sphingosine 1-phosphate have properties that may limit t

50 ngolipid metabolism, especially ceramide and sphingosine 1-phosphate, have been linked to colon cance

51 affic elicited by nonrelated agents, such as sphingosine 1-phosphate (i.e., transient alpha1B-AR-Rab5

52 expression was increased by cell stretch and sphingosine 1-phosphate in a RhoA-dependent manner, and

53 Functions of sphingosine kinase or sphingosine-1-phosphate in pathogenic protozoans are vir

54 , which phosphorylate sphingosine to produce sphingosine 1-phosphate, in kidney fibrosis induced by f

55 In mammals, sphingosine-1-phosphate is a powerful signalling molecul

56 ncreased cellular ceramide levels, decreased sphingosine 1-phosphate levels, and acted synergisticall

57 slocation of sphingosine kinase-1, increased sphingosine-1-phosphate levels, and Akt phosphorylation.

58 nt drop in SMPDL3b protein, sphingosine, and sphingosine-1-phosphate levels.

59 1 has emerged as an important determinant of sphingosine-1-phosphate lung levels, which, when aberran

60 iant, we describe the novel interaction with sphingosine 1-phosphate lyase (SGPL1)-a key enzyme for t

61 neumophila translocates the effector protein sphingosine-1 phosphate lyase (LpSpl) to target the host

62 rome caused by loss-of-function mutations in sphingosine-1-phosphate lyase (SGPL1).

63 and demonstrate that inhibiting the enzyme, sphingosine-1-phosphate lyase 1 (SPL), has neuroprotecti

64 he expression of sphingosine kinase 1 and 2, sphingosine-1-phosphate lyase 1, and sphingosine-1-phosp

65 omal interacting molecule-1 (STIM1), whereas sphingosine-1-phosphate-mediated enhancement of endothel

66 hesion molecule-1 expression, treatment with sphingosine-1-phosphate or SEW (sphingosine-1-phosphate

67 edicts that these variants affect binding of sphingosine-1-phosphate (p.Arg108Pro) and G protein dock

68 ls by activation of the sphingosine kinase-1/sphingosine-1-phosphate pathway, resulting in improvemen

69 and 2, sphingosine-1-phosphate lyase 1, and sphingosine-1-phosphate phosphatase 1 in normal human li

70 Sphingosine-1-phosphate phosphatase 2 promotes disruptio

71 he actions of two S1P-specific phosphatases, sphingosine-1-phosphate phosphatases 1 and 2.

72 f sphingosine kinase 1 (SphK1) and increases sphingosine 1-phosphate production in adipocytes in a ma

73 While inhibition of sphingosine-1-phosphate production did not alter hBD exp

74 lceramide, glucosylsphingosine, sphingosine, sphingosine-1-phosphate) promote alpha-synuclein aggrega

75 Here, we show that the sphingosine 1-phosphate receptor (S1PR) modulator fingol

76 Sphingosine 1-phosphate receptor 1 (S1P1) plays a pivota

77 Sphingosine 1-phosphate receptor 1 (S1P1), a G protein-c

78 Whereas the role of sphingosine 1-phosphate receptor 1 (S1PR1) in T cell egr

79 targets, including the key migratory factor sphingosine 1-phosphate receptor 1 (S1PR1).

80 Endothelial cells were stimulated with sphingosine 1-phosphate receptor 1 agonists to determine

81 th sphingosine 1-phosphate, FTY720, or other sphingosine 1-phosphate receptor 1 agonists.

82 L/6 mice with bleomycin to assess effects of sphingosine 1-phosphate receptor 1 agonists.

83 ves a malicious amplification loop involving sphingosine 1-phosphate receptor 1 and the NF-kappaB/IL-

84 red mice maintains significantly higher lung sphingosine 1-phosphate receptor 1 expression compared w

85 receptor 1 agonists to determine effects on sphingosine 1-phosphate receptor 1 expression.

86 r-promoting agent that effectively maintains sphingosine 1-phosphate receptor 1 levels and improves o

87 Synthetic sphingosine 1-phosphate receptor 1 modulators constitute

88 FTY720 (S)-phosphonate maintains endothelial sphingosine 1-phosphate receptor 1 protein expression in

89 e does not induce beta-arrestin recruitment, sphingosine 1-phosphate receptor 1 ubiquitination, and p

90 Reduction of sphingosine 1-phosphate receptor 1 with small interferen

91 he cell surface and consequent activation of sphingosine 1-phosphate receptor 1, Src and Fyn tyrosine

92 We demonstrate here that local sphingosine 1-phosphate receptor 3 (S1P3) agonism recrui

93 Sphingosine 1-phosphate and the sphingosine 1-phosphate receptor agonist FTY720 did not

94 Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is effective

95 in-mediated cell growth and survival via the sphingosine 1-phosphate receptor subtype 2 (S1P2) follow

96 the beta2 adrenergic receptor (beta2AR), the sphingosine 1-phosphate receptor-1 (S1P1), or the kappa-

97 An established role of sphingosine 1-phosphate receptor-1 in T cells is to guid

98 lial sphingosine 1-phosphate signals through sphingosine 1-phosphate receptor-1 to prevent mitochondr

99 contrasting with the proposed access for the sphingosine 1-phosphate receptor.

100 adenosine receptors, dopamine receptor, and sphingosine 1-phosphate receptor.

101 Sphingosine-1 phosphate receptor 1 (S1P1) is critical fo

102 Previously, we showed that levels of sphingosine-1 phosphate receptor 3 (S1PR3) are increased

103 IVIg or F(ab')2 fragments decrease the sphingosine-1 phosphate receptor on CD4 cells, thus sequ

104 use they down-regulate the expression of the sphingosine-1 phosphate receptor-1, which mediates the e

105 as 5-fold greater selectivity for binding to sphingosine-1-phosphate receptor (S1PR) 1 (S1PR(1)) vers

106 cent data have demonstrated the potential of sphingosine-1-phosphate receptor (S1PR) agonism in the t

107 termine the impact of fingolimod (FTY720), a sphingosine-1-phosphate receptor (S1PR) agonist, on 2 mo

108 iated through S1P binding to specific GPCRs [sphingosine-1-phosphate receptor (S1PR)1-5] and some oth

109 Activation of the GPCR sphingosine-1-phosphate receptor 1 (S1P1) by sphingosine

110 nic lymphocyte accumulation involved reduced sphingosine-1-phosphate receptor 1 (S1P1) expression and

111 Furthermore, deletion of the sphingosine-1-phosphate receptor 1 (S1P1) in these precu

112 by utilizing the clinically important GPCR, sphingosine-1-phosphate receptor 1 (S1P1).

113 pability and increased surface expression of sphingosine-1-phosphate receptor 1 (S1P1).

114 phingosine-related therapeutics, agonists of sphingosine-1-phosphate receptor 1 (S1P1).

115 The sphingosine-1-phosphate receptor 1 (S1PR1) and beta1-adr

116 S1P1 (sphingosine-1-phosphate receptor 1) agonists prevent lym

117 lipoprotein M-deficient mice is dependent on sphingosine-1-phosphate receptor 1.

118 neutralizing anti-S1P antibody (mAb) and the sphingosine-1-phosphate receptor 2 (S1PR2) antagonist JT

119 We identified sphingosine-1-phosphate receptor 2 (S1PR2) as a sex- and

120 We find that the sphingosine-1-phosphate receptor 2 (S1PR2) is repressed

121 act via HSPGs independently of its receptor, Sphingosine-1-Phosphate receptor 2 (S1PR2).

122 Here we investigate the role of sphingosine-1-phosphate receptor 3 (S1PR3) in regulating

123 Notably, these cells express the sphingosine-1-phosphate receptor 3 (S1PR3), and stimulat

124 and this was attenuated by inhibition of the sphingosine-1-phosphate receptor 3 (S1PR3).

125 significantly upregulated the expression of sphingosine-1-phosphate receptor 4 on neutrophils, and t

126 strongly support a cardioprotective role for sphingosine-1-phosphate receptor activation during MI.

127 We hypothesized that sphingosine-1-phosphate receptor activation with fingoli

128 Sphingosine-1-phosphate receptor activation with fingoli

129 /HI administration of FTY720 (fingolimod), a sphingosine-1-phosphate receptor agonist that blocks lym

130 Mice lacking MZ B cells, or treated with a sphingosine-1-phosphate receptor agonist to dislocate th

131 eatment with sphingosine-1-phosphate or SEW (sphingosine-1-phosphate receptor agonist) remained effec

132 Fingolimod, a sphingosine-1-phosphate receptor agonist, is used for th

133 that expression of CD69, by interfering with sphingosine-1-phosphate receptor function, is a critical

134 th the transcriptional downregulation of the sphingosine-1-phosphate receptor S1P1.

135 Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that i

136 ible mouse model with a temporally disrupted sphingosine-1-phosphate receptor-1 (S1PR1) gene specific

137 cular B-cell egress via the marginal zone is sphingosine-1-phosphate receptor-1 (S1PR1)-dependent.

138 the sphingosine kinase-1 inhibitor, and the sphingosine-1-phosphate receptor-1/-3 antagonist VPC2301

139 Work in mice showed that sphingosine-1-phosphate receptor-2 (S1PR2), a Galpha12 a

140 uencing revealed a Thr289Arg substitution in Sphingosine-1-Phosphate Receptor-2 (S1pr2).

141 lls from lymph nodes in the mouse depends on sphingosine-1-phosphate receptor-3.

142 s such as vasa, pumilio and piwi, as well as sphingosine-1-phosphate receptor.

143 enitor cells (NSCs) in vitro via a PAR1-PAR3-sphingosine-1-phosphate-receptor 1-Akt pathway, which su

144 inhibit PP2A and that FTY720-P, acting as a sphingosine-1-phosphate-receptor-1 agonist, elicits sign

145 phate (S1P) is the endogenous ligand for the sphingosine 1-phosphate receptors (S1P1-5) and evokes a

146 The sphingosine-1-phosphate receptors (S1PRs) are a well-stu

147 ific protease activated receptors (PARs) and sphingosine-1-phosphate receptors (S1PRs), in that siRNA

148 This pathway consists of cell-surface sphingosine-1-phosphate receptors, an intracellular casc

149 signals mediated by chemokine, integrin, and sphingosine-1-phosphate receptors.

150 ation of surface-expressed G protein-coupled sphingosine-1-phosphate receptors.

151 These data demonstrate that local sphingosine-1-phosphate release after PDPN-CLEC-2-mediat

152 ts toward an important role for the ceramide/sphingosine-1-phosphate rheostat in maintaining lung cel

153 uned by cellular concentrations of SphK1 and sphingosine 1 phosphate (S1P).

154 nase 1 (SPHK1) generates the bioactive lipid sphingosine 1-phosphate (S1P) and has established roles

155 K-Ras(V12) downregulates the bioactive lipid sphingosine 1-phosphate (S1P) and its receptor S1P2, bot

156 lysophospholipids lysophosphatidic acid and sphingosine 1-phosphate (S1P) are generated during injur

157 Sphingosine 1-phosphate (S1P) binds G-protein-coupled re

158 Apolipoprotein M (apoM), a plasma sphingosine 1-phosphate (S1P) carrier, associates with p

159 ses (Sphks), which catalyze the formation of sphingosine 1-phosphate (S1P) from sphingosine, have bee

160 The chemoattractant sphingosine 1-phosphate (S1P) guides T cell circulation

161 Sphingosine 1-phosphate (S1P) is a bioactive lipid that

162 Sphingosine 1-phosphate (S1P) is a bioactive lipid that

163 Sphingosine 1-phosphate (S1P) is a bioactive lipid whose

164 The bioactive lipid sphingosine 1-phosphate (S1P) is a degradation product o

165 Sphingosine 1-phosphate (S1P) is a lipid mediator formed

166 Sphingosine 1-phosphate (S1P) is a multifunctional bioac

167 Sphingosine 1-phosphate (S1P) is a pleiotropic bioactive

168 Sphingosine 1-phosphate (S1P) is a pleiotropic signaling

169 Sphingosine 1-phosphate (S1P) is a pleiotropic signaling

170 Sphingosine 1-phosphate (S1P) is a sphingolipid and the

171 Elevated sphingosine 1-phosphate (S1P) is detrimental in Sickle C

172 Sphingosine 1-phosphate (S1P) is involved in multiple pa

173 Sphingosine 1-phosphate (S1P) is the endogenous ligand f

174 Here, we show that sphingosine 1-phosphate (S1P) levels are not only increa

175 Sphingosine 1-phosphate (S1P) lyase (SPL) is an intracel

176 Sphingosine 1-phosphate (S1P) lyase has recently been im

177 l compartmentalization of the lipid mediator sphingosine 1-phosphate (S1P) may be one such mechanism.

178 Our previous microarray data indicated sphingosine 1-phosphate (S1P) metabolism and signalling

179 enhances PP2A activity independently of the sphingosine 1-phosphate (S1P) pathway was unknown.

180 Sphingosine 1-phosphate (S1P) produces significant endot

181 e kinase 1 (SK1), the enzyme responsible for sphingosine 1-phosphate (S1P) production, is overexpress

182 cent data have demonstrated the potential of sphingosine 1-phosphate (S1P) receptor (S1PR) agonism in

183 In this study, we identify the sphingosine 1-phosphate (S1P) receptor 1 (S1P1) as one o

184 eport the BBB-regulatory role of endothelial sphingosine 1-phosphate (S1P) receptor-1, a G protein-co

185 Modulation of sphingosine 1-phosphate (S1P) receptors in a non-selecti

186 trafficking is orchestrated by chemokine and sphingosine 1-phosphate (S1P) receptors that enable homi

187 Here we generated a sphingosine 1-phosphate (S1P) reporter mouse and used th

188 The ceramide-sphingosine 1-phosphate (S1P) rheostat is important in r

189 Receptor-mediated sphingosine 1-phosphate (S1P) signaling is known to infl

190 Modulation of sphingosine 1-phosphate (S1P) signaling represents a sol

191 , and lymphatic vessel development, required sphingosine 1-phosphate (S1P) signaling via the G protei

192 Sphingosine 1-phosphate (S1P) signaling, however, is als

193 ermined that provision of the lipid mediator sphingosine 1-phosphate (S1P) to the systemic circulatio

194 Sphingosine 1-phosphate (S1P), a bioactive lipid involve

195 associates with plasma HDL and binds plasma sphingosine 1-phosphate (S1P), a signaling molecule acti

196 osine kinase 1, which catalyses formation of sphingosine 1-phosphate (S1P), in promoting the differen

197 One of these intermediates, sphingosine 1-phosphate (S1P), is stored at high concent

198 Sphingosine 1-phosphate (S1P), the natural sphingolipid

199 ular thyroid ML-1 cancer cells, sphingolipid sphingosine 1-phosphate (S1P), through S1P receptors 1 a

200 To extrude, a cell produces the lipid, Sphingosine 1-Phosphate (S1P), which activates S1P(2) re

201 However, CCL19 and sphingosine 1-phosphate (S1P), which control homeostatic

202 howed that osteoclasts produce the chemokine sphingosine 1-phosphate (S1P), which stimulates osteobla

203 S) B cells exhibited enhanced sensitivity to sphingosine 1-phosphate (S1P).

204 gent, thrombin, and barrier-enhancing agent, sphingosine 1-phosphate (S1P).

205 sphingosine kinase 1 (SK1) and its product, sphingosine 1-phosphate (S1P).

206 gosine to the promitogenic/migratory product sphingosine 1-phosphate (S1P).

207 codes a transporter for the signalling lipid sphingosine 1-phosphate (S1P).

208 (p < 0.01) Gb3 ganglioside (-50 +/- 3%) and sphingosine 1-phosphate (S1P, -40 +/- 4%), which ended u

209 lymphoid tissues depends on the presence of sphingosine-1 phosphate (S1P) and the regulated expressi

210 The role of sphingosine-1 phosphate (S1P) in leukocyte trafficking h

211 vestigated the role of the crosstalk between sphingosine-1-phosphate (S1P) and cytokine signaling cas

212 In zebrafish, signaling mediated by sphingosine-1-phosphate (S1P) and its cognate G protein-

213 The bioactive sphingolipid sphingosine-1-phosphate (S1P) and the kinase that produc

214 though the bioactive sphingolipid metabolite sphingosine-1-phosphate (S1P) and the kinase that produc

215 Serum levels of the lipid mediator sphingosine-1-phosphate (S1P) are reduced in septic pati

216 hat skin mast cell (MC) activation and local sphingosine-1-phosphate (S1P) are significantly augmente

217 ansforming growth factor beta (TGF-beta) and sphingosine-1-phosphate (S1P) contribute to the pathogen

218 report a role for HGF-induced intracellular sphingosine-1-phosphate (S1P) generation catalyzed by sp

219 ive immunity and involves chemotaxis along a sphingosine-1-phosphate (S1P) gradient.

220 tissues into the circulation is dependent on sphingosine-1-phosphate (S1P) gradients, sensed by S1P r

221 ansport cells that respond to chemokines and sphingosine-1-phosphate (S1P) gradients.

222 sphingolipids ceramide-1-phosphate (C1P) and sphingosine-1-phosphate (S1P) have emerged as key regula

223 , we show that accumulation of intracellular sphingosine-1-phosphate (S1P) impairs the metabolism of

224 suggesting involvement of phospholipids like sphingosine-1-phosphate (S1P) in AKR1B10's oncogenic fun

225 Apolipoprotein M (ApoM) transports sphingosine-1-phosphate (S1P) in plasma, and ApoM-defici

226 cal roles for the sphingolipids ceramide and sphingosine-1-phosphate (S1P) in the regulation of ERM p

227 Chronic sphingosine-1-phosphate (S1P) infusion resulted in a dev

228 Sphingosine-1-phosphate (S1P) is a bioactive lipid media

229 Sphingosine-1-phosphate (S1P) is a bioactive lipid that

230 Sphingosine-1-phosphate (S1P) is a bioactive signalling

231 Sphingosine-1-phosphate (S1P) is a bioactive sphingolipi

232 Sphingosine-1-phosphate (S1P) is a bioactive sphingolipi

233 Sphingosine-1-phosphate (S1P) is a bioactive sphingolipi

234 Sphingosine-1-phosphate (S1P) is a constituent of high-d

235 For example, circulating sphingosine-1-phosphate (S1P) is a key regulator of lymp

236 Sphingosine-1-phosphate (S1P) is a lysophospholipid that

237 Sphingosine-1-phosphate (S1P) is emerging as a potent mo

238 Sphingosine-1-phosphate (S1P) is generated through phosp

239 osure of neonatal mice to hyperoxia enhanced sphingosine-1-phosphate (S1P) levels in lung tissues; ho

240 Sphingosine-1-phosphate (S1P) lyase (SPL) irreversibly d

241 recessive mutations in SGPL1, which encodes sphingosine-1-phosphate (S1P) lyase.

242 The bioactive sphingolipid sphingosine-1-phosphate (S1P) mediates cellular prolifer

243 Sphingosine-1-phosphate (S1P) mediates egress of immune

244 GPCRs for thrombin and sphingosine-1-phosphate (S1P) on human glioblastoma cell

245 We show that sphingosine-1-phosphate (S1P) produced by upregulation o

246 e to subtoxic levels of ER stress, increased sphingosine-1-phosphate (S1P) production activates an NF

247 concomitantly generates sphingosine used for sphingosine-1-phosphate (S1P) production.

248 Administration of an immunomodulatory sphingosine-1-phosphate (S1P) receptor 1 (S1P1R) agonist

249 Sphingosine-1-phosphate (S1P) receptor 1 (S1PR1) is crit

250 s study, we showed that the egress receptor, sphingosine-1-phosphate (S1P) receptor 1 (S1PR1), was ex

251 Inactivating mutations in the sphingosine-1-phosphate (S1P) receptor 2 (S1PR2) promote

252 ihydrogen phosphate ester) is a nonselective sphingosine-1-phosphate (S1P) receptor agonist thought t

253 The sphingosine-1-phosphate (S1P) receptor signaling system

254 gic receptors (ARs) and the cardioprotective sphingosine-1-phosphate (S1P) receptor-1 (S1PR1).

255 Sphingosine-1-phosphate (S1P) receptors are critical for

256 We examined the expression and function of sphingosine-1-phosphate (S1P) receptors in human thymocy

257 sphingosine-1-phosphate receptor 1 (S1P1) by sphingosine-1-phosphate (S1P) regulates key physiologica

258 IV-1+ lymph node (LN) through impairments in sphingosine-1-phosphate (S1P) responsiveness.

259 demonstrate that LRP1 modulates Gi-dependent sphingosine-1-phosphate (S1P) signaling and integrates S

260 These results demonstrate a role for sphingosine-1-phosphate (S1P) signaling in B. pertussis-

261 Sphingosine-1-phosphate (S1P) signaling is essential for

262 The oral drug FTY720 affects sphingosine-1-phosphate (S1P) signaling on targeted cell

263 the elevation of myogenic tone via enhanced sphingosine-1-phosphate (S1P) signaling.

264 The sphingolipid sphingosine-1-phosphate (S1P) signals through five G-pro

265 In vitro, sphingosine-1-phosphate (S1P) stimulates migration of ge

266 Because sphingosine-1-phosphate (S1P) strengthens AJs, we determ

267 tion in pulmonary metastasis was observed in sphingosine-1-phosphate (S1P) transporter spinster homol

268 Ca(2+) mobilization by sphingosine-1-phosphate (S1P) was also attenuated by CFT

269 However, levels of sphingosine-1-phosphate (S1P) were significantly increas

270 Membrane sphingolipids are metabolized to sphingosine-1-phosphate (S1P), a bioactive lipid mediato

271 hingosine kinase-1, an enzyme that generates sphingosine-1-phosphate (S1P), a bioactive lipid mediato

272 osine kinases 1 (SK1) and 2 (SK2) synthesize sphingosine-1-phosphate (S1P), a bioactive lipid messeng

273 L) catalyzes the irreversible degradation of sphingosine-1-phosphate (S1P), a bioactive lipid whose s

274 Sphingosine-1-phosphate (S1P), a bioactive sphingolipid

275 Sphingosine-1-phosphate (S1P), a bioactive sphingolipid

276 polymerization-promoting cyclic peptide, or sphingosine-1-phosphate (S1P), a follicular fluid consti

277 Sphingosine-1-phosphate (S1P), a ligand for 5 specific r

278 othelial barrier-protective bioactive lipid, sphingosine-1-phosphate (S1P), could ameliorate the micr

279 A bioactive lipid, sphingosine-1-phosphate (S1P), has been suggested to aff

280 eoclasts, which contained elevated levels of sphingosine-1-phosphate (S1P), increased alkaline phosph

281 the native state, but can be metabolized to sphingosine-1-phosphate (S1P), linked to inflammation an

282 pathology, we investigated the metabolism of Sphingosine-1-phosphate (S1P), one of the most important

283 t a signaling lipid, the ceramide metabolite sphingosine-1-phosphate (S1P), regulates production of a

284 yonic pancreata, and genomics, we found that sphingosine-1-phosphate (S1p), signalling through the G

285 Sphingosine-1-phosphate (S1P), which is produced by 2 sp

286 Th17 cells stimulated with cl-CD95L produced sphingosine-1-phosphate (S1P), which promoted endothelia

287 iator and G protein-coupled receptor agonist sphingosine-1-phosphate (S1P).

288 pid sphingosine, leading to the formation of sphingosine-1-phosphate (S1P).

289 ble cleavage of the lipid-signaling molecule sphingosine-1-phosphate (S1P).

290 om the action of its phosphate metabolite on sphingosine-1-phosphate S1P1 receptors, while a variety

291 te the thymic and lymph node egress defects, sphingosine-1-phosphate signaling was not obviously pert

292 ngolipid phosphatase SGPP1, an antagonist of sphingosine-1-phosphate signaling, as a target of miR-95

293 . (2017) now show that lymphatic endothelial sphingosine 1-phosphate signals through sphingosine 1-ph

294 Sphingosine 1-phosphate (SP1) receptors may be attractiv

295 ed TAZ activity upon a second stimulus (i.e. sphingosine 1-phosphate) that induced nuclear TAZ transl

296 laimed that TRAF2 RING requires a co-factor, sphingosine-1-phosphate, that is generated by the enzyme

297 CK1 and vimentin were both up-regulated with sphingosine 1-phosphate treatment, required for invasion

298 e of a reporter for the signaling lipid S1P (sphingosine 1-phosphate), we found that cells sensed hig

299 al cells, promoting synthesis and release of sphingosine-1 phosphate, which inhibits trafficking of T

300 ch disrupt endothelial barrier function, and sphingosine-1-phosphate, which stabilizes barrier functi